Product Introduction :
Crizotinib is a multi-target protein kinase inhibitor developed by Pfizer Inc., USA. It has been shown to have significant clinical efficacy in patients with tumors with abnormal ALK, ROS1 and MET kinase activity. Crizotinib (Chinese trade name: Xalcoli) was launched in China in 2013.
Clinical trials have shown that for patients with ALK-positive advanced non-small cell lung cancer, the efficacy of crizotinib is significantly better than traditional chemotherapy. The median progression-free survival (PFS) of patients treated with first-line monotherapy is 10.9 months, with an effective rate of 74%. The median PFS of patients treated with second-line monotherapy is 7.7 months, with an effective rate of 65.3%. In September 2014, the New England Journal of Medicine published the results of a phase 1 extended clinical study of crizotinib in patients with ROS1-positive advanced non-small cell lung cancer. In this study, the overall response rate of crizotinib in ROS1-positive non-small cell lung cancer reached 72%. The median duration of response was 17.6 months, the median PFS was 19.2 months, and the type of ROS1 fusion gene did not affect the efficacy.
Indications:
Indicated for the treatment of locally advanced and metastatic non-small cell lung cancer (NSCLC) that is positive for anaplastic lymphoma kinase (ALK/ROS1/MET)
Usage and Dosage:
The recommended dose is 250 mg orally twice a day
